OKYO Pharma Limited
NASDAQ:OKYOBiotechnology
+$0.01 today
- Market cap
- $57.73M
- Beta
- 0.02
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.12
Volume 0.24M
Average 0.07M
OKYO Total Liabilities
Everything the company owes to creditors and other parties.
OKYO Pharma LimitedNASDAQ: OKYO
Total Liabilities · Q2 FY2026 · quarter ended Sep 2025
Total liabilities falls 19.8% from a year ago
Total liabilities stood at $8.06M at the end of Q2 FY2026, down 19.8% from a year earlier. Over 3 fiscal years it compounded at +89.6% a year.
Context
- Total liabilities amounted to 173.5% of total assets at the end of Q2 FY2026, down 181.9 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -19.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 9.23M USD
- Year-over-year change
- +24.3%
- 4-year CAGR
- +51.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | 9.23M | +24.3% |
| FY2024 | 2024-03-31 | 7.42M | +2.3% |
| FY2023 | 2023-03-31 | 7.26M | +436.3% |
| FY2022 | 2022-03-31 | 1.35M | -23.6% |
| FY2021 | 2021-03-31 | 1.77M | — |
Total Liabilities vs competitors
How OKYO compares with its peers on the latest reported figures
- OKYO's Sep 2025 total liabilities of $8.06M is the 8th highest of the 10 companies compared; the peer median is $11.45M.
- Its year-over-year change of -19.8% is the 8th highest of 10, against a peer median of +3.7%.
- Total liabilities amounts to 173.5% of total assets for OKYO, versus a peer median of 18.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $196.68M | +35.2% | +10.9% | 90.3% | |
| Mar 2026 | $70.39M | -20.6% | -15.2% | 27.8% | |
| Mar 2026 | $40.47M | +33.6% | -4.7% | 186.8% | |
| Mar 2026 | $37.43M | -57.3% | +5.7% | 18.5% | |
| Mar 2026 | $11.45M | +11.2% | +84.9% | 12.0% | |
| Dec 2025 | $11.44M | +55.7% | +18.3% | 99.5% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $11.06M | -9.9% | -17.5% | 8.7% |
| Sep 2025 | $8.06M | -19.8% | +89.6% | 173.5% | |
| Mar 2026 | $7.14M | +3.7% | +17.2% | 12.2% | |
| Mar 2026 | $4.3M | -14.6% | -25.6% | 8.1% | |
| Peer median (excluding OKYO) | $11.45M | +3.7% | +5.7% | 18.5% | |
Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6.89M | 2.7M | 4.05M | 826.85K | 1.56M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 4.5K | 883.44K | 980.08K | 580.94K | 1.89M |
| Inventory | 34 | (1.49K) | 170.31K | 0 | 0 |
| Other Current Assets | 71.75K | 1.49K | (170.31K) | 0 | 0 |
| Total Current Assets | 6.99M | 4.3M | 5.2M | 1.54M | 3.68M |
| Property, Plant & Equipment (Net) | 104.64K | 5.23K | 7.22K | 3.35K | 2.04K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 104.64K | 5.23K | 7.22K | 3.35K | 2.04K |
| Total Assets | 7.09M | 4.3M | 5.2M | 1.54M | 3.68M |
| Account Payables | 210.99K | 517.67K | 1.02M | 6.13M | 7.9M |
| Short-term Debt | 34.14K | 0 | 2.22M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.43M | 323.06K | 1.29M | 7.1M | 9.04M |
| Total Current Liabilities | 1.71M | 1.35M | 7.26M | 7.42M | 9.23M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 64.61K | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.77M | 1.35M | 7.26M | 7.42M | 9.23M |
| Common Stock | 0 | 123.98M | 0 | 143.11M | 0 |
| Retained Earnings | (99.4M) | (112.43M) | (125.7M) | (142.52M) | (143.02M) |
| Accumulated OCI | 12.82M | (11.01M) | (7.74M) | (11.31M) | (11.47M) |
| Other Stockholders Equity | (1) | 2.41M | 173 | 4.84M | 2.23M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 5.32M | 2.95M | (2.05M) | (5.88M) | (5.55M) |
| Total Debt | 98.76K | 0 | 2.22M | 0 | 0 |
| Net Debt | (6.79M) | (2.7M) | (1.83M) | (826.85K) | (1.56M) |
OKYO Pharma Limited
NASDAQ:OKYO
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.